Novo Nordisk received authorization from Chinese regulators to market Wegovy for the treatment of Metabolic Dysfunction-Associated Steatohepatitis. The approval makes the drug the first and only GLP-1 receptor agonist cleared in China for this liver condition, giving the company an exclusive regulatory foothold in the region.

The medication is a blockbuster weight loss treatment marketed globally. This new authorization expands the drug's clinical application in China, establishing the sole approved GLP-1 receptor agonist for the treatment of MASH.